Takeda adds CAR T therapies
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) is adding chimeric antigen receptor (CAR) T cell therapies to its oncology pipeline by partnering with Noile-Immune Biotech Inc. (Tokyo, Japan). Takeda will pay an undisclosed technology access fee and make an equity investment in Noile-Immune, and will receive an exclusive option to develop and commercialize products in Noile-Immune's pipeline and those that result from the partnership.
Noile-Immune has an exclusive license to a next generation CAR T platform from Yamaguchi University professor Koji Tamada. Tamada is the founder, director, and chief science and medical officer of Noile-Immune. The companies aim to use the platform, which produces cytokines, chemokines and other molecules, to influence the solid tumor microenvironment...